{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:03:19Z","timestamp":1787014999307,"version":"build-2736575974"},"reference-count":25,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2005,8,5]],"date-time":"2005-08-05T00:00:00Z","timestamp":1123200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2005,9]]},"abstract":"<jats:p>\n                    <jats:bold>Abstract:\u2002<\/jats:bold>\n                    <jats:italic>Objectives:<\/jats:italic>\n                    \u2002To analyse outcome and prognostic factors in non\u2010Hodgkin's lymphoma (NHL) patients who progress after autologous stem cell transplantation (ASCT).\n                    <jats:italic>Patients:<\/jats:italic>\n                    \u2002Altogether 115 consecutive NHL patients transplanted in 1991\u20132000 were studied. Histology included diffuse large B cell (\n                    <jats:italic>n<\/jats:italic>\n                    \u2003=\u200352), follicular (\n                    <jats:italic>n<\/jats:italic>\n                    \u2003=\u200326), mantle cell (\n                    <jats:italic>n<\/jats:italic>\n                    \u2003=\u200315), T cell (\n                    <jats:italic>n<\/jats:italic>\n                    \u2003=\u200316) and other subtypes (\n                    <jats:italic>n<\/jats:italic>\n                    \u2003=\u20036). The median time from ASCT to the progression was 7\u2003months. Ninety\u2010six patients (83%) received salvage treatment.\n                    <jats:italic>Results:<\/jats:italic>\n                    \u2002Twenty\u2010four patients (25%) achieved complete remission and 30 (31%) partial remission. The median overall survival was 8\u2003months (range 0\u201398+) and the projected 4\u2010year survival 21%. In multivariate analysis factors predicting treatment response after the progression included the use of rituximab (\n                    <jats:italic>P<\/jats:italic>\n                    \u2003=\u20030.036), histology other than diffuse large B cell (\n                    <jats:italic>P<\/jats:italic>\n                    \u2003=\u20030.001) and International Prognostic Index \u22642 at progression (\n                    <jats:italic>P<\/jats:italic>\n                    \u2003&lt;\u20030.001). Normal lactate dehydrogenase (LDH) at progression (\n                    <jats:italic>P<\/jats:italic>\n                    \u2003=\u20030.002), response to salvage treatment (\n                    <jats:italic>P<\/jats:italic>\n                    \u2003&lt;\u20030.001) and time from ASCT to progression \u22657\u2003months (\n                    <jats:italic>P<\/jats:italic>\n                    \u2003=\u20030.022) were predictors for overall survival.\n                    <jats:italic>Conclusions:<\/jats:italic>\n                    \u2002Although the prognosis of patients who progress after ASCT is generally poor, many patients will respond to current therapies, and some may experience prolonged survival. Normal LDH at time of disease progression and longer time to progression after ASCT were the most powerful predictors for a promising outcome.\n                  <\/jats:p>","DOI":"10.1111\/j.1600-0609.2005.00481.x","type":"journal-article","created":{"date-parts":[[2005,8,5]],"date-time":"2005-08-05T12:26:59Z","timestamp":1123244819000},"page":"199-205","source":"Crossref","is-referenced-by-count":9,"title":["Outcome of progressive disease after autologous stem cell transplantation in patients with non\u2010Hodgkin's lymphoma: a nation\u2010wide survey"],"prefix":"10.1111","volume":"75","author":[{"given":"T.","family":"Kuittinen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Wiklund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Remes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Elonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Lehtinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Kuittinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lepp\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Putkonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"R\u00e4ty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Turpeenniemi\u2010Hujanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Nousiainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Jantunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,8,5]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704653"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512073332305"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2003.00093.x"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2476"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh069"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190290026286"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.023"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0982"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V80.8.2142.2142"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609045716"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1081\/CNV-120001174"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1080\/1024533031000107479"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704214"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703888"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"e_1_2_6_17_2","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"Revised European\u2010American classification of lymphoid neoplasm: a proposal from the international lymphoma study group","volume":"84","author":"Harris NL","year":"1994","journal-title":"Blood"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"issue":"6500","key":"e_1_2_6_19_2","first-page":"558","article-title":"Randomized intergroup trial first line treatment <60\u2003years with diffuse large B cell non\u2010Hodgkin's lymphoma (DLBCL) with a Chop\u2010like regimen with or without the anti\u2010CD20 antibody rituximab","volume":"22","author":"Pfreundschsh MG","year":"2004","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00130404-200209000-00007"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.06.055"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700989"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-472X(00)00511-7"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1083-8791(03)00241-6"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-01-0231"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200545"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2005.00481.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2005.00481.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T20:54:00Z","timestamp":1695761640000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2005.00481.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,5]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["10.1111\/j.1600-0609.2005.00481.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2005.00481.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8,5]]}}}